(PRESS RELEASE) RIDGEWOOD, NJ — reVision Therapeutics Inc., a privately held early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, announced that it has signed an exclusive license agreement with Cornell University. The agreement is for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision.
“The Cornell license represents a significant milestone for reVision and underscores the Company’s commitment to innovative therapies and treatments for unmet medical needs associated with genetic and progressive vision loss,” said Paul Fehlner, reVision’s president and CEO. “We believe this will enable us to accelerate the development of our Stargardt disease treatment, which was the basis for founding reVision. We would like to congratulate the Cornell research team for their superb work in elucidating a novel mechanism of action to treat this devastating disease.”
“We are pleased that reVision will develop a treatment option for Stargardt patients based on our scientific discoveries,” said Marcelo Nociari, PhD, assistant professor of Immunology in Ophthalmology, Weill Cornell Medical College, co-inventor of US Patent No. 10,463,687, which is part of the license agreement. “There are no current treatment options for Stargardt disease, which often manifests in childhood and leads to legal blindness within the second or third decade of life. reVision has assembled a team with proven expertise and passion for advancing life-changing eye therapies.”
“This is an important opportunity for reVision to work with Cornell to find a treatment for retinal diseases like Stargardt,” said Brian Brooks, MD, PhD, of the National Eye Institute, a reVision scientific adviser. “With no approved treatment for Stargardt, we need to find ways to preserve vision and improve Stargardt patients’ quality of life.”